"People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and the related health benefits, but many doctors at weight-loss clinics are noticing a puzzling response in certain individuals. Andres J. Acosta, a gastroenterologist at the Mayo Clinic, says some of his patients have expressed frustration and disappointment as they watch friends or colleagues drop significant weight while taking the drugs but lose little or no weight themselveseven when they adhere to the medication's instructions perfectly."
"About 12 percent of Americans have reported using one of the new drugsknown as glucagon-like peptide 1 (GLP-1) receptor agonistsfor weight loss. Real-world data show that as many as one in four people on these drugs are nonresponders, which many experts define as those who lose less than 5 percent of their body weight after three months of taking a GLP-1 drug. (Five percent is the threshold above which people start to see improvements in health.)"
GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) have produced substantial weight loss for many users, but a notable minority do not respond. Real-world data and clinical trials indicate up to about 23–25 percent of patients lose less than 5 percent of body weight after three months, a level below the threshold for common health improvements. Higher semaglutide dosing did not reduce the proportion of nonresponders in recent trials. Researchers are investigating underlying biological causes to understand why individuals vary so widely in their response to these medications.
Read at www.scientificamerican.com
Unable to calculate read time
Collection
[
|
...
]